Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center
proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.